Congratulations to Dr. Tami Rashal on her new role as Chief Medical Officer at SBH Sciences and SBH Bioventure! With her impressive background in hematology-oncology, clinical research, and drug development, there’s no doubt she will make a significant impact. Wishing Tami and the SBH team great success in expanding their medical and regulatory capabilities! Looking forward to seeing the exciting advancements ahead. #Congratulations #Biotech #ClinicalResearch #Leadership
SBH Sciences is thrilled to welcome Dr. Tami Rashal Rashal as our new Chief Medical Officer (CMO) for SBH Sciences and SBH Bioventure. Dr. Rashal is a distinguished, board-certified hematologist-oncologist and entrepreneur with over a decade of experience in clinical research, drug development, and hospital practice. She has successfully led the submission of three NDAs and multiple INDs, proving her expertise in advancing novel therapies to her patients. Before joining SBH Sciences. Dr. Rashal was the CEO of Merlin Health, an AI-based clinical trial decision-making tool, where she demonstrated her ability to drive complex projects and lead high-performing cross-functional teams to success. Dr. Rashal’s vision for SBH Sciences includes expanding our offerings in the following key areas: ?? Comprehensive IND submission support ?? Medical and regulatory strategy development ?? Protocol design and clinical trial execution ??Enhanced medical affairs, including Key Opinion Leaders (KOL) engagement, opening KOL labs, and advancing PDX models In addition to expanding SBH’s service offerings, Dr. Rashal will focus on supporting biotech startups, leading due diligence, and fostering opportunities for non-dilutive funding to ensure long-term success and sustainability. Her strategic insights and collaborative approach will play a key role in SBH Sciences’ continued growth and success. Welcome to the team, Dr. Rashal!